Exploring early biomarkers for treatment response in head and neck cancer
Exploratory Study of Early Biomarkers Allowing Dynamic Assessment of Response to Treatment in Cancers of the Head and Neck
This study is trying to find early signs in blood, saliva, and tissue samples that show how well people with head and neck cancer are responding to immunotherapy, so treatments can be better tailored for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Royal Marsden NHS Foundation Trust Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT05644457 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify early biomarkers that can indicate how well patients with head and neck squamous cell carcinoma respond to immunotherapy. By collecting blood, saliva, and cancer tissue samples from patients undergoing treatment, the researchers will analyze changes in these samples to track treatment effectiveness. The study also involves growing cancer samples in the lab to evaluate their growth behavior and response to various treatments. This approach could help tailor more effective treatment strategies for patients with advanced head and neck cancer.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with recurrent or locally advanced head and neck cancer who are receiving immunotherapy.
Not a fit: Patients who are pregnant or unable to undergo serial sample collection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment plans for patients with head and neck cancer, improving their chances of survival.
How similar studies have performed: Other studies have shown promise in using biomarkers to assess treatment response in various cancers, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Patients with histologically confirmed cancer of the head and neck with evidence of recurrent or locally advanced cancer not suitable for treatment with curative intent, or metastatic disease. * Receiving immunotherapy * Ability to give informed consent for biological sample collection. Exclusion Criteria: * Unable to undergo serial sample collection * Pregnancy
Where this trial is running
London
- The Royal Marsden Hospital — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Ben O'Leary
- Email: ben.oleary@icr.ac.uk
- Phone: 02071535337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.